Home Featured Page 268

Featured

Latest

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine, and Scientific Rigour

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

Ketanserin’s Contributions to Psychedelic Research

Should Society Legalize Psychedelics? A Breakdown of the Intelligence Squared Debate

PTSF57 – New Compounds, Psychedelic Business, and Neurogenesis

COMPASS Pathways announces pricing of public offering

Numinus Wellness Q2 2021 Results Highlighted by $17.25 Million Financing, Mindspace...

Op-Ed: Re-evaluating the Results of the Recent Trial of Psilocybin vs...

Bexson Biomedical Granted USPTO Patent On Proprietary Ketamine Formulation

Tryp Therapeutics Announces Q2 2021 Financial Results

Small Pharma Completes Reverse Take-Over Transaction

MINDCURE Shares Update on Strong Financial Position, Near Term Revenue Drivers...

EDITOR PICKS

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine,...

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.